Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Caliber Imaging & Diagnostics's Total Liabilities for the quarter that ended in Mar. 2014 was $16.40 Mil. Caliber Imaging & Diagnostics's Total Assets for the quarter that ended in Mar. 2014 was $2.21 Mil.
Therefore, Caliber Imaging & Diagnostics's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2014 was 7.41.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Caliber Imaging & Diagnostics Liabilities-to-Assets Related Terms
Caliber Imaging & Diagnostics Liabilities-to-Assets Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LCDX vs VICA, CRVW, RSLS: Liabilities-to-Assets Comparison
For the Medical Devices subindustry, Caliber Imaging & Diagnostics's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Caliber Imaging & Diagnostics Liabilities-to-Assets vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Caliber Imaging & Diagnostics's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Caliber Imaging & Diagnostics's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Caliber Imaging & Diagnostics's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2013 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Caliber Imaging & Diagnostics (LCDX) has a Liabilities-to-Assets of 7.41 as of Mar. 2014. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Caliber Imaging & Diagnostics and its competitors.
Is Caliber Imaging & Diagnostics' Liabilities-to-Assets too high?
Caliber Imaging & Diagnostics' current Liabilities-to-Assets is 7.41.
How does Caliber Imaging & Diagnostics' Liabilities-to-Assets compare to VICA and CRVW?
Caliber Imaging & Diagnostics' Liabilities-to-Assets of 7.41 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Medical Devices & Instruments company?
A good Liabilities-to-Assets depends on the Medical Devices & Instruments industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Caliber Imaging & Diagnostics and its competitors. Caliber Imaging & Diagnostics's current Liabilities-to-Assets is 7.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caliber Imaging & Diagnostics stock overvalued right now?
Caliber Imaging & Diagnostics (LCDX) has a current Liabilities-to-Assets of 7.41. The current Liabilities-to-Assets is 7.41. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Caliber Imaging & Diagnostics (LCDX), the current Liabilities-to-Assets is 7.41 as of Mar. 2014. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Caliber Imaging & Diagnostics Business Description
Caliber Imaging & Diagnostics Inc is a medical device company engaged in developing, manufacturing, marketing & selling point-of-care cellular imaging systems to diagnose skin cancer. It offers clinical imaging and research imaging solutions that shows tissue at the cellular level. Its products portfolio includes; VivaScope; VivaScope 3000, 1500 & 2500; and VivaNet and VivaScan.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LCDX has been successfully added to your 
